Related Experiment Videos
Antiatherosclerotic activity of drugs in relation to nitric oxide function
H Bult1, A G Herman, K E Matthys
1Department of Medicine, University of Antwerp (UIA), Belgium. bult@uia.ua.ac.be
Abstract:
Many studies have shown that loss of endothelium-derived nitric oxide is a major factor of ischemic episodes in patients with coronary artery disease and there is increasing evidence to suggest that nitric oxide might exert antiatherosclerotic actions. Based on these concepts, the results of animal studies on the effects of lipid lowering drugs, antioxidants, angiotensin converting enzyme inhibitors, Ca2+ channel blockers, estrogens and agents which modulate nitric oxide bioavailability are presented and compared to the results of patient studies and clinical trials. In spite of encouraging results obtained with antioxidants in animals, clinical trials could only show a clear positive effect of vitamin E treatment on the outcome of cardiovascular disease. Angiotensin converting enzyme inhibitors can ameliorate endothelial dysfunction in coronary heart disease, but their impact on disease progression remains unclear. There is evidence that estrogen replacement therapy in post-menopausal women may increase the bioavailability of nitric oxide. Finally, improved endothelial function and plaque stability clearly contribute to the clinical benefits of lipid lowering interventions, statins in particular. Taken together, these studies lend support to the concept that improving endothelial function and nitric oxide release might serve as valuable elements in the prevention or therapy of cardiovascular disease.
Insights
Loss of nitric oxide contributes to ischemic episodes in coronary artery disease. Improving nitric oxide bioavailability and endothelial function may help prevent or treat cardiovascular disease.
Area of Science:
- Cardiovascular Medicine
- Pharmacology
Background:
- Endothelium-derived nitric oxide (NO) plays a crucial role in cardiovascular health.
- Loss of NO is linked to ischemic episodes in coronary artery disease (CAD).
- NO may possess antiatherosclerotic properties.
Purpose of the Study:
- To review and compare animal and human studies on interventions affecting nitric oxide bioavailability.
- To evaluate the potential of various drugs and therapies in preventing or treating cardiovascular disease by targeting NO.
Main Methods:
- Comparative analysis of animal studies and clinical trials.
- Review of literature on lipid-lowering drugs, antioxidants, ACE inhibitors, calcium channel blockers, and estrogens.
- Assessment of agents modulating nitric oxide bioavailability.
Main Results:
- Antioxidants showed promise in animals, but only Vitamin E demonstrated clear clinical benefits.
- ACE inhibitors may improve endothelial dysfunction in CAD, but their effect on disease progression is uncertain.
- Estrogen therapy may enhance NO bioavailability in post-menopausal women.
- Lipid-lowering interventions, especially statins, improve endothelial function and plaque stability.
Conclusions:
- Improving endothelial function and nitric oxide release are promising strategies for cardiovascular disease prevention and therapy.
- Targeting NO bioavailability offers a potential therapeutic avenue for cardiovascular conditions.